COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)

被引：0
|
作者：
Dixon, M. [1 ]
Gu, J. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO53
引用
收藏
页码：S313 / S314
页数：2
相关论文
共 50 条
  • [31] Real-world (RW) biomarker characteristics and clinical outcomes in pretreated non-MSI-H/dMMR metastatic colorectal cancer (mCRC) patients
    Amonkar, Mayur M.
    Sura, Sneha
    Desai, Kaushal
    Jain, Rishi
    Liu, Zhimei
    Niehoff, Nicole
    Wilson, Thomas W.
    Patton, Gregory
    Cosgrove, David
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
    Taieb, J.
    Bouche, O.
    Andre, T.
    Barbier, E.
    Laurent-Puig, P.
    Bez, J.
    Toullec, C.
    Borg, C.
    Randrian, V.
    Evesque, L.
    Corbinais, S.
    Buecher, B.
    Perrier, H.
    Di Fiore, F.
    Gallois, C.
    Lepage, C.
    El Hajbi, F.
    Tougeron, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1391
  • [33] Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy (P) after FDA approval.
    Snow, Tamara
    Swaminathan, Akshay
    Snider, Jeremy
    Schrock, Alexa Betzig
    Li, Gerald
    Alexander, Brian Michael
    Singal, Gaurav
    Castellanos, Emily
    McCusker, Margaret Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
    Kaili Yang
    Lu Han
    Shikai Wu
    Xiujuan Qu
    Qin Li
    Chuanhua Zhao
    Jing Zhou
    Xuan Jin
    Yusheng Wang
    Dong Yan
    Zhiqiang Cheng
    Yuwei Hua
    Yan Zhang
    Yang Ge
    Jinghua Sun
    Wei Deng
    Lin Zhao
    Yunbo Zhao
    Cancer Immunology, Immunotherapy, 2022, 71 : 1443 - 1451
  • [35] Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
    Yang, Kaili
    Han, Lu
    Wu, Shikai
    Qu, Xiujuan
    Li, Qin
    Zhao, Chuanhua
    Zhou, Jing
    Jin, Xuan
    Wang, Yusheng
    Yan, Dong
    Cheng, Zhiqiang
    Hua, Yuwei
    Zhang, Yan
    Ge, Yang
    Sun, Jinghua
    Deng, Wei
    Zhao, Lin
    Zhao, Yunbo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1443 - 1451
  • [36] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
    Aguiar-Ibanez, Raquel
    Hardern, Chloe
    van Hees, Frank
    Lee, Dawn
    Patel, Anubhav
    Chhabra, Nitika
    Baluni, Gargi
    Amonkar, Mayur
    Lai, Yizhen
    Xu, Ruifeng
    Massaad, Rachid
    Fogelman, David
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 469 - 480
  • [37] Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France
    Cohen, R.
    Andre, T.
    Roset, M.
    Amonkar, M.
    Renna, P.
    Lara, N.
    Kothari, S.
    Tougeron, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S170 - S171
  • [38] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
    Emidio, O.
    Iqbal, Z.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
  • [39] Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
    Wang, Z.
    Fu, H.
    Huiyan, L.
    Wang, F.
    Wang, D.
    Li, Y.
    Li, D.
    Jin, Y.
    Zhang, D.
    Lu, Z.
    Chen, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1513 - S1514
  • [40] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
12345